ID   CSPG4_HUMAN             Reviewed;        2322 AA.
AC   Q6UVK1; D3DW77; Q92675;
DT   13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   28-JUN-2023, entry version 166.
DE   RecName: Full=Chondroitin sulfate proteoglycan 4;
DE   AltName: Full=Chondroitin sulfate proteoglycan NG2;
DE   AltName: Full=Melanoma chondroitin sulfate proteoglycan;
DE   AltName: Full=Melanoma-associated chondroitin sulfate proteoglycan;
DE   Flags: Precursor;
GN   Name=CSPG4; Synonyms=MCSP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Melanoma;
RX   PubMed=8790396; DOI=10.1073/pnas.93.18.9710;
RA   Pluschke G., Vanek M., Evans A., Dittmar T., Schmid P., Itin P.,
RA   Filardo E.J., Reisfeld R.A.;
RT   "Molecular cloning of a human melanoma-associated chondroitin sulfate
RT   proteoglycan.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:9710-9715(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Melanoma;
RX   PubMed=15210734; DOI=10.1083/jcb.200403174;
RA   Yang J., Price M.A., Neudauer C.L., Wilson C., Ferrone S., Xia H., Iida J.,
RA   Simpson M.A., McCarthy J.B.;
RT   "Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation
RT   by distinct mechanisms.";
RL   J. Cell Biol. 165:881-891(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH ITGA4.
RX   PubMed=9488735; DOI=10.1074/jbc.273.10.5955;
RA   Iida J., Meijne A.M.L., Oegema T.R. Jr., Yednock T.A., Kovach N.L.,
RA   Furcht L.T., McCarthy J.B.;
RT   "A role of chondroitin sulfate glycosaminoglycan binding site in
RT   alpha4beta1 integrin-mediated melanoma cell adhesion.";
RL   J. Biol. Chem. 273:5955-5962(1998).
RN   [6]
RP   INTERACTION WITH BCAR1; CDC42 AND ACK1, AND FUNCTION.
RX   PubMed=10587647; DOI=10.1038/70302;
RA   Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L.,
RA   Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.;
RT   "Melanoma chondroitin sulphate proteoglycan regulates cell spreading
RT   through Cdc42, Ack-1 and p130cas.";
RL   Nat. Cell Biol. 1:507-513(1999).
RN   [7]
RP   INTERACTION WITH MMP16, AND FUNCTION.
RX   PubMed=11278606; DOI=10.1074/jbc.m010053200;
RA   Iida J., Pei D., Kang T., Simpson M.A., Herlyn M., Furcht L.T.,
RA   McCarthy J.B.;
RT   "Melanoma chondroitin sulfate proteoglycan regulates matrix
RT   metalloproteinase-dependent human melanoma invasion into type I collagen.";
RL   J. Biol. Chem. 276:18786-18794(2001).
RN   [8]
RP   IDENTIFICATION OF CSPG REPEATS.
RX   PubMed=12220645; DOI=10.1016/s0014-5793(02)03195-2;
RA   Staub E., Hinzmann B., Rosenthal A.;
RT   "A novel repeat in the melanoma-associated chondroitin sulfate proteoglycan
RT   defines a new protein family.";
RL   FEBS Lett. 527:114-118(2002).
RN   [9]
RP   INTERACTION WITH ITGA3; ITGB1 AND LGALS3.
RX   PubMed=15181153; DOI=10.1091/mbc.e04-03-0236;
RA   Fukushi J., Makagiansar I.T., Stallcup W.B.;
RT   "NG2 proteoglycan promotes endothelial cell motility and angiogenesis via
RT   engagement of galectin-3 and alpha3beta1 integrin.";
RL   Mol. Biol. Cell 15:3580-3590(2004).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-2075.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [11]
RP   INTERACTION WITH C.DIFFICILE TCDB (MICROBIAL INFECTION).
RX   PubMed=25547119; DOI=10.1038/cr.2014.169;
RA   Yuan P., Zhang H., Cai C., Zhu S., Zhou Y., Yang X., He R., Li C., Guo S.,
RA   Li S., Huang T., Perez-Cordon G., Feng H., Wei W.;
RT   "Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for
RT   Clostridium difficile toxin B.";
RL   Cell Res. 25:157-168(2015).
RN   [12]
RP   INTERACTION WITH C.DIFFICILE TCDB (MICROBIAL INFECTION).
RX   PubMed=27680706; DOI=10.1038/nature19799;
RA   Tao L., Zhang J., Meraner P., Tovaglieri A., Wu X., Gerhard R., Zhang X.,
RA   Stallcup W.B., Miao J., He X., Hurdle J.G., Breault D.T., Brass A.L.,
RA   Dong M.;
RT   "Frizzled proteins are colonic epithelial receptors for C. difficile toxin
RT   B.";
RL   Nature 538:350-355(2016).
RN   [13]
RP   INTERACTION WITH C.DIFFICILE TCDB (MICROBIAL INFECTION).
RX   PubMed=31233493; DOI=10.1371/journal.pbio.3000311;
RA   Simeon R., Jiang M., Chamoun-Emanuelli A.M., Yu H., Zhang Y., Meng R.,
RA   Peng Z., Jakana J., Zhang J., Feng H., Chen Z.;
RT   "Selection and characterization of ultrahigh potency designed ankyrin
RT   repeat protein inhibitors of C. difficile toxin B.";
RL   PLoS Biol. 17:e3000311-e3000311(2019).
RN   [14]
RP   TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-995.
RX   PubMed=32337544; DOI=10.1093/glycob/cwaa039;
RA   Toledo A.G., Pihl J., Spliid C.B., Persson A., Nilsson J., Pereira M.A.,
RA   Gustavsson T., Choudhary S., Oo H.Z., Black P.C., Daugaard M., Esko J.D.,
RA   Larson G., Salanti A., Clausen T.M.;
RT   "An affinity chromatography and glycoproteomics workflow to profile the
RT   chondroitin sulfate proteoglycans that interact with malarial VAR2CSA in
RT   the placenta and in cancer.";
RL   Glycobiology 30:989-1002(2020).
RN   [15]
RP   TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-995.
RX   PubMed=36213313; DOI=10.1007/s42485-022-00092-3;
RA   Ramarajan M.G., Saraswat M., Budhraja R., Garapati K., Raymond K.,
RA   Pandey A.;
RT   "Mass spectrometric analysis of chondroitin sulfate-linked peptides.";
RL   J. Proteins Proteom. 13:187-203(2022).
CC   -!- FUNCTION: Proteoglycan playing a role in cell proliferation and
CC       migration which stimulates endothelial cells motility during
CC       microvascular morphogenesis. May also inhibit neurite outgrowth and
CC       growth cone collapse during axon regeneration. Cell surface receptor
CC       for collagen alpha 2(VI) which may confer cells ability to migrate on
CC       that substrate. Binds through its extracellular N-terminus growth
CC       factors, extracellular matrix proteases modulating their activity. May
CC       regulate MPP16-dependent degradation and invasion of type I collagen
CC       participating in melanoma cells invasion properties. May modulate the
CC       plasminogen system by enhancing plasminogen activation and inhibiting
CC       angiostatin. Functions also as a signal transducing protein by binding
CC       through its cytoplasmic C-terminus scaffolding and signaling proteins.
CC       May promote retraction fiber formation and cell polarization through
CC       Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated
CC       adhesion and spreading by recruiting and activating a signaling cascade
CC       through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling
CC       cascades. {ECO:0000269|PubMed:10587647, ECO:0000269|PubMed:11278606,
CC       ECO:0000269|PubMed:15210734}.
CC   -!- SUBUNIT: Interacts with the first PDZ domain of MPDZ. Interacts with
CC       PRKCA. Binds TNC, laminin-1, COL5A1 and COL6A2. Interacts with PLG and
CC       angiostatin. Binds FGF2 and PDGFA. Interacts with GRIP1, GRIP2 and
CC       GRIA2. Forms a ternary complex with GRIP1 and GRIA2 (By similarity).
CC       Interacts with LGALS3 and the integrin composed of ITGB1 and ITGA3.
CC       Interacts with ITGA4 through its chondroitin sulfate glycosaminoglycan.
CC       Interacts with BCAR1, CDC42 and ACK1. Interacts with MMP16.
CC       {ECO:0000250, ECO:0000269|PubMed:10587647, ECO:0000269|PubMed:11278606,
CC       ECO:0000269|PubMed:15181153, ECO:0000269|PubMed:9488735}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.difficile toxin TcdB,
CC       suggesting that it may act as a receptor for TcdB.
CC       {ECO:0000269|PubMed:25547119, ECO:0000269|PubMed:27680706,
CC       ECO:0000269|PubMed:31233493}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q00657};
CC       Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q00657};
CC       Extracellular side {ECO:0000250|UniProtKB:Q00657}. Apical cell membrane
CC       {ECO:0000250|UniProtKB:Q00657}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:Q00657}; Extracellular side
CC       {ECO:0000250|UniProtKB:Q00657}. Cell projection, lamellipodium membrane
CC       {ECO:0000250|UniProtKB:Q00657}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:Q00657}; Extracellular side
CC       {ECO:0000250|UniProtKB:Q00657}. Cell surface
CC       {ECO:0000250|UniProtKB:Q00657}. Note=Localized at the apical plasma
CC       membrane it relocalizes to the lamellipodia of astrocytoma upon
CC       phosphorylation by PRKCA. Localizes to the retraction fibers. Localizes
CC       to the plasma membrane of oligodendrocytes (By similarity).
CC       {ECO:0000250|UniProtKB:Q00657, ECO:0000250|UniProtKB:Q8VHY0}.
CC   -!- TISSUE SPECIFICITY: Detected in fibroblasts (at protein level)
CC       (PubMed:36213313). Detected in placenta (at protein level)
CC       (PubMed:32337544). Detected in malignant melanoma cells.
CC       {ECO:0000269|PubMed:32337544, ECO:0000269|PubMed:36213313,
CC       ECO:0000269|PubMed:8790396}.
CC   -!- PTM: O-glycosylated; contains glycosaminoglycan chondroitin sulfate
CC       which are required for proper localization and function in stress fiber
CC       formation (By similarity). Involved in interaction with MMP16 and
CC       ITGA4. {ECO:0000250, ECO:0000269|PubMed:16335952}.
CC   -!- PTM: Phosphorylation by PRKCA regulates its subcellular location and
CC       function in cell motility. {ECO:0000250}.
CC   -!- MISCELLANEOUS: Valuable marker for several incompletely differentiated
CC       precursor cells.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X96753; CAA65529.1; -; mRNA.
DR   EMBL; AY359468; AAQ62842.1; -; mRNA.
DR   EMBL; AC105020; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471136; EAW99239.1; -; Genomic_DNA.
DR   EMBL; CH471136; EAW99240.1; -; Genomic_DNA.
DR   CCDS; CCDS10284.1; -.
DR   RefSeq; NP_001888.2; NM_001897.4.
DR   PDB; 7ML7; EM; 3.17 A; B=30-764.
DR   PDB; 7N8X; EM; 3.40 A; B=411-550.
DR   PDB; 7N9Y; EM; 4.80 A; B=411-550.
DR   PDBsum; 7ML7; -.
DR   PDBsum; 7N8X; -.
DR   PDBsum; 7N9Y; -.
DR   AlphaFoldDB; Q6UVK1; -.
DR   SMR; Q6UVK1; -.
DR   BioGRID; 107846; 149.
DR   CORUM; Q6UVK1; -.
DR   IntAct; Q6UVK1; 23.
DR   MINT; Q6UVK1; -.
DR   STRING; 9606.ENSP00000312506; -.
DR   GlyConnect; 2028; 1 N-Linked glycan (1 site).
DR   GlyCosmos; Q6UVK1; 18 sites, 5 glycans.
DR   GlyGen; Q6UVK1; 19 sites, 2 N-linked glycans (1 site), 4 O-linked glycans (3 sites).
DR   iPTMnet; Q6UVK1; -.
DR   PhosphoSitePlus; Q6UVK1; -.
DR   BioMuta; CSPG4; -.
DR   DMDM; 296434468; -.
DR   EPD; Q6UVK1; -.
DR   jPOST; Q6UVK1; -.
DR   MassIVE; Q6UVK1; -.
DR   MaxQB; Q6UVK1; -.
DR   PaxDb; Q6UVK1; -.
DR   PeptideAtlas; Q6UVK1; -.
DR   ProteomicsDB; 67431; -.
DR   ABCD; Q6UVK1; 53 sequenced antibodies.
DR   Antibodypedia; 1108; 827 antibodies from 40 providers.
DR   DNASU; 1464; -.
DR   Ensembl; ENST00000308508.5; ENSP00000312506.5; ENSG00000173546.7.
DR   GeneID; 1464; -.
DR   KEGG; hsa:1464; -.
DR   MANE-Select; ENST00000308508.5; ENSP00000312506.5; NM_001897.5; NP_001888.2.
DR   UCSC; uc002baw.3; human.
DR   AGR; HGNC:2466; -.
DR   CTD; 1464; -.
DR   DisGeNET; 1464; -.
DR   GeneCards; CSPG4; -.
DR   HGNC; HGNC:2466; CSPG4.
DR   HPA; ENSG00000173546; Tissue enhanced (intestine).
DR   MIM; 601172; gene.
DR   neXtProt; NX_Q6UVK1; -.
DR   OpenTargets; ENSG00000173546; -.
DR   PharmGKB; PA26963; -.
DR   VEuPathDB; HostDB:ENSG00000173546; -.
DR   eggNOG; KOG3597; Eukaryota.
DR   GeneTree; ENSGT00940000154091; -.
DR   HOGENOM; CLU_000473_1_0_1; -.
DR   InParanoid; Q6UVK1; -.
DR   OMA; PWPQGTT; -.
DR   OrthoDB; 4072625at2759; -.
DR   PhylomeDB; Q6UVK1; -.
DR   TreeFam; TF316876; -.
DR   PathwayCommons; Q6UVK1; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022870; Chondroitin sulfate biosynthesis.
DR   Reactome; R-HSA-2022923; Dermatan sulfate biosynthesis.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3595172; Defective CHST3 causes SEDCJD.
DR   Reactome; R-HSA-3595174; Defective CHST14 causes EDS, musculocontractural type.
DR   Reactome; R-HSA-3595177; Defective CHSY1 causes TPBS.
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   SignaLink; Q6UVK1; -.
DR   SIGNOR; Q6UVK1; -.
DR   BioGRID-ORCS; 1464; 30 hits in 1150 CRISPR screens.
DR   ChiTaRS; CSPG4; human.
DR   GeneWiki; CSPG4; -.
DR   GenomeRNAi; 1464; -.
DR   Pharos; Q6UVK1; Tbio.
DR   PRO; PR:Q6UVK1; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q6UVK1; protein.
DR   Bgee; ENSG00000173546; Expressed in tendon of biceps brachii and 131 other tissues.
DR   Genevisible; Q6UVK1; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0009986; C:cell surface; HDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001726; C:ruffle; IEA:Ensembl.
DR   GO; GO:0015026; F:coreceptor activity; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0008347; P:glial cell migration; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0097178; P:ruffle assembly; IEA:Ensembl.
DR   GO; GO:0006929; P:substrate-dependent cell migration; IEA:Ensembl.
DR   GO; GO:0048771; P:tissue remodeling; IEA:UniProtKB-KW.
DR   CDD; cd00110; LamG; 2.
DR   Gene3D; 2.60.120.200; -; 2.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR039005; CSPG_rpt.
DR   InterPro; IPR001791; Laminin_G.
DR   PANTHER; PTHR45739; MATRIX PROTEIN, PUTATIVE-RELATED; 1.
DR   PANTHER; PTHR45739:SF8; TNFR-CYS DOMAIN-CONTAINING PROTEIN; 1.
DR   Pfam; PF16184; Cadherin_3; 13.
DR   Pfam; PF00054; Laminin_G_1; 1.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   SMART; SM00282; LamG; 2.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   PROSITE; PS51854; CSPG; 15.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; Cell membrane; Cell projection;
KW   Developmental protein; Differentiation; Disulfide bond; Glycoprotein;
KW   Membrane; Phosphoprotein; Proteoglycan; Reference proteome; Repeat; Signal;
KW   Tissue remodeling; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000255"
FT   CHAIN           30..2322
FT                   /note="Chondroitin sulfate proteoglycan 4"
FT                   /id="PRO_0000041962"
FT   TOPO_DOM        30..2224
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:Q00657"
FT   TRANSMEM        2225..2245
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        2246..2322
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q00657"
FT   DOMAIN          30..192
FT                   /note="Laminin G-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          202..380
FT                   /note="Laminin G-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   REPEAT          428..523
FT                   /note="CSPG 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          553..645
FT                   /note="CSPG 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          662..764
FT                   /note="CSPG 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          783..878
FT                   /note="CSPG 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          898..989
FT                   /note="CSPG 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1018..1110
FT                   /note="CSPG 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1126..1216
FT                   /note="CSPG 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1238..1337
FT                   /note="CSPG 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1356..1449
FT                   /note="CSPG 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1473..1563
FT                   /note="CSPG 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1581..1679
FT                   /note="CSPG 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1704..1803
FT                   /note="CSPG 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1832..1924
FT                   /note="CSPG 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          1941..2029
FT                   /note="CSPG 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REPEAT          2038..2147
FT                   /note="CSPG 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01201,
FT                   ECO:0000269|PubMed:12220645"
FT   REGION          30..639
FT                   /note="Globular or compact configuration stabilized by
FT                   disulfide bonds"
FT   REGION          30..639
FT                   /note="Neurite growth inhibition"
FT                   /evidence="ECO:0000250"
FT   REGION          574..1040
FT                   /note="Interaction with COL6A2"
FT                   /evidence="ECO:0000250"
FT   REGION          631..1446
FT                   /note="Interaction with COL5A1"
FT                   /evidence="ECO:0000250"
FT   REGION          1586..2221
FT                   /note="Neurite growth inhibition"
FT                   /evidence="ECO:0000250"
FT   REGION          1587..2221
FT                   /note="Cysteine-containing"
FT   REGION          2182..2206
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           2320..2322
FT                   /note="PDZ-binding"
FT   MOD_RES         2252
FT                   /note="Phosphothreonine; by PKC/PRKCA"
FT                   /evidence="ECO:0000250|UniProtKB:Q00657"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        348
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        427
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        685
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        772
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        995
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000269|PubMed:32337544,
FT                   ECO:0000269|PubMed:36213313"
FT   CARBOHYD        1131
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1202
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1364
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1449
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1645
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1909
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2016
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2034
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2040
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2075
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   DISULFID        169..192
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DISULFID        354..380
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   VARIANT         1703
FT                   /note="R -> H (in dbSNP:rs8023621)"
FT                   /id="VAR_061733"
FT   CONFLICT        5..6
FT                   /note="PR -> RG (in Ref. 1; CAA65529 and 2; AAQ62842)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        477..478
FT                   /note="RH -> HY (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        486
FT                   /note="P -> L (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        631
FT                   /note="R -> C (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        715..717
FT                   /note="QGA -> HST (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        942
FT                   /note="H -> L (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1208
FT                   /note="R -> E (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1405
FT                   /note="A -> P (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1557
FT                   /note="R -> P (in Ref. 1; CAA65529)"
FT                   /evidence="ECO:0000305"
FT   HELIX           423..425
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          431..434
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          437..443
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   TURN            449..451
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          452..456
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   TURN            458..462
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   HELIX           465..467
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          472..474
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          477..479
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          493..495
FT                   /evidence="ECO:0007829|PDB:7N8X"
FT   HELIX           496..500
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          504..507
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          516..524
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   HELIX           533..536
FT                   /evidence="ECO:0007829|PDB:7ML7"
FT   STRAND          538..547
FT                   /evidence="ECO:0007829|PDB:7ML7"
SQ   SEQUENCE   2322 AA;  250537 MW;  0B4F39AFC5ADD3CA CRC64;
     MQSGPRPPLP APGLALALTL TMLARLASAA SFFGENHLEV PVATALTDID LQLQFSTSQP
     EALLLLAAGP ADHLLLQLYS GRLQVRLVLG QEELRLQTPA ETLLSDSIPH TVVLTVVEGW
     ATLSVDGFLN ASSAVPGAPL EVPYGLFVGG TGTLGLPYLR GTSRPLRGCL HAATLNGRSL
     LRPLTPDVHE GCAEEFSASD DVALGFSGPH SLAAFPAWGT QDEGTLEFTL TTQSRQAPLA
     FQAGGRRGDF IYVDIFEGHL RAVVEKGQGT VLLHNSVPVA DGQPHEVSVH INAHRLEISV
     DQYPTHTSNR GVLSYLEPRG SLLLGGLDAE ASRHLQEHRL GLTPEATNAS LLGCMEDLSV
     NGQRRGLREA LLTRNMAAGC RLEEEEYEDD AYGHYEAFST LAPEAWPAME LPEPCVPEPG
     LPPVFANFTQ LLTISPLVVA EGGTAWLEWR HVQPTLDLME AELRKSQVLF SVTRGARHGE
     LELDIPGAQA RKMFTLLDVV NRKARFIHDG SEDTSDQLVL EVSVTARVPM PSCLRRGQTY
     LLPIQVNPVN DPPHIIFPHG SLMVILEHTQ KPLGPEVFQA YDPDSACEGL TFQVLGTSSG
     LPVERRDQPG EPATEFSCRE LEAGSLVYVH RGGPAQDLTF RVSDGLQASP PATLKVVAIR
     PAIQIHRSTG LRLAQGSAMP ILPANLSVET NAVGQDVSVL FRVTGALQFG ELQKQGAGGV
     EGAEWWATQA FHQRDVEQGR VRYLSTDPQH HAYDTVENLA LEVQVGQEIL SNLSFPVTIQ
     RATVWMLRLE PLHTQNTQQE TLTTAHLEAT LEEAGPSPPT FHYEVVQAPR KGNLQLQGTR
     LSDGQGFTQD DIQAGRVTYG ATARASEAVE DTFRFRVTAP PYFSPLYTFP IHIGGDPDAP
     VLTNVLLVVP EGGEGVLSAD HLFVKSLNSA SYLYEVMERP RHGRLAWRGT QDKTTMVTSF
     TNEDLLRGRL VYQHDDSETT EDDIPFVATR QGESSGDMAW EEVRGVFRVA IQPVNDHAPV
     QTISRIFHVA RGGRRLLTTD DVAFSDADSG FADAQLVLTR KDLLFGSIVA VDEPTRPIYR
     FTQEDLRKRR VLFVHSGADR GWIQLQVSDG QHQATALLEV QASEPYLRVA NGSSLVVPQG
     GQGTIDTAVL HLDTNLDIRS GDEVHYHVTA GPRWGQLVRA GQPATAFSQQ DLLDGAVLYS
     HNGSLSPRDT MAFSVEAGPV HTDATLQVTI ALEGPLAPLK LVRHKKIYVF QGEAAEIRRD
     QLEAAQEAVP PADIVFSVKS PPSAGYLVMV SRGALADEPP SLDPVQSFSQ EAVDTGRVLY
     LHSRPEAWSD AFSLDVASGL GAPLEGVLVE LEVLPAAIPL EAQNFSVPEG GSLTLAPPLL
     RVSGPYFPTL LGLSLQVLEP PQHGALQKED GPQARTLSAF SWRMVEEQLI RYVHDGSETL
     TDSFVLMANA SEMDRQSHPV AFTVTVLPVN DQPPILTTNT GLQMWEGATA PIPAEALRST
     DGDSGSEDLV YTIEQPSNGR VVLRGAPGTE VRSFTQAQLD GGLVLFSHRG TLDGGFRFRL
     SDGEHTSPGH FFRVTAQKQV LLSLKGSQTL TVCPGSVQPL SSQTLRASSS AGTDPQLLLY
     RVVRGPQLGR LFHAQQDSTG EALVNFTQAE VYAGNILYEH EMPPEPFWEA HDTLELQLSS
     PPARDVAATL AVAVSFEAAC PQRPSHLWKN KGLWVPEGQR ARITVAALDA SNLLASVPSP
     QRSEHDVLFQ VTQFPSRGQL LVSEEPLHAG QPHFLQSQLA AGQLVYAHGG GGTQQDGFHF
     RAHLQGPAGA SVAGPQTSEA FAITVRDVNE RPPQPQASVP LRLTRGSRAP ISRAQLSVVD
     PDSAPGEIEY EVQRAPHNGF LSLVGGGLGP VTRFTQADVD SGRLAFVANG SSVAGIFQLS
     MSDGASPPLP MSLAVDILPS AIEVQLRAPL EVPQALGRSS LSQQQLRVVS DREEPEAAYR
     LIQGPQYGHL LVGGRPTSAF SQFQIDQGEV VFAFTNFSSS HDHFRVLALA RGVNASAVVN
     VTVRALLHVW AGGPWPQGAT LRLDPTVLDA GELANRTGSV PRFRLLEGPR HGRVVRVPRA
     RTEPGGSQLV EQFTQQDLED GRLGLEVGRP EGRAPGPAGD SLTLELWAQG VPPAVASLDF
     ATEPYNAARP YSVALLSVPE AARTEAGKPE SSTPTGEPGP MASSPEPAVA KGGFLSFLEA
     NMFSVIIPMC LVLLLLALIL PLLFYLRKRN KTGKHDVQVL TAKPRNGLAG DTETFRKVEP
     GQAIPLTAVP GQGPPPGGQP DPELLQFCRT PNPALKNGQY WV
//
